NEWS
Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform
Modular Medical (NASDAQ:MODD) has announced a proof-of-concept studywith Gubra A/S to explore the potential use of its MODD1 pump platform for delivering short-acting peptides as an alternative for patients who discontinue long-acting GLP-1 formulations. The study will use a high-fat, diet-induced obese (DIO) mouse model to determine if an FDA-approved, short-acting peptide delivered via pump can provide comparable glycemic control and weight loss with improved tolerability for people with type 2 diabetes and obesity.
This research aims to address the high discontinuation rates of GLP-1 drugs due to tolerability issues, cost, and inconsistent efficacy. Modular Medical believes that pump technology could simplify and improve dosing regimens for short-acting peptides, potentially offering a more personalized and tolerable solution for patients who struggle with long-acting GLP-1 therapies.
This research aims to address the high discontinuation rates of GLP-1 drugs due to tolerability issues, cost, and inconsistent efficacy. Modular Medical believes that pump technology could simplify and improve dosing regimens for short-acting peptides, potentially offering a more personalized and tolerable solution for patients who struggle with long-acting GLP-1 therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment